Ontario to Spend $2.2 Billion on Indigenous Role in Mining
The Ontario government will spend nearly C$3.1 billion ($2.2 billion) to encourage Indigenous participation in the mining industry, in a bid to ramp up critical minerals production across Canada's most populous province.
Premier Doug Ford's government said Wednesday that most of the money will go to loan guarantees that enable Indigenous business groups to invest in Ontario mining projects. Funds will also go toward grants and scholarships for Indigenous students interested in careers in mining and resource development.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Gizmodo
an hour ago
- Gizmodo
HP 14″ Laptop With Office For Life Is Cheaper Than AirPods, Amazon Is Clearing Stock at 74% Off
Purchasing a proper Windows laptop from respected brands like HP, Dell, or Lenovo generally costs you over $1,000. But right now, Amazon has a deal that is nearly too good to ignore: there's an HP 14 laptop (385GB storage, 16GB RAM) available for an all-time low price of just $359 which is a huge 72% discount from its normal $1,299 price. It also includes a bundle of extras that make it even more valuable: a one-time Microsoft Office license for life, a DVD drive for free, and a Micro-SD card with 256GB of storage space for extra room. With such a low price and so many premium features included, this HP laptop is a steal. See at Amazon Perfect Laptop for Day to Day Tasks At the heart of this HP 14 lLaptop is an Intel N150 processor with 4 cores and 4 thread, capable of reaching speeds up to 3.2 GHz. This configuration ensures good and smooth multitasking whether you're juggling multiple browser tabs, working on documents or streaming content. The laptop comes with 16GB of DDR4 RAM and 128GB of ultra-fast UFS storage, offering snappy performance and quick access to files and applications. For those who need even more space, the included 256GB Micro-SD card provides ample room for storing more documents. The 14-inch BrightView HD anti-glare display features micro-edge bezels and it is ideal for entertainment-oriented gameplay or uncluttered dual-monitor set-ups. The screen offers vibrant colors and sharp text so that your content can come life while watching movies, photo editing, or creating presentations. The thin and light design, weighing just 3.24 pounds and measuring 0.71 inches thick makes it a breeze to take back and forth from class to class or on a business adventure. Thanks to battery life of up to 11 hours of video play and the benefit of fast-charge technology, you can maintain productivity and entertainment all day long. It includes the newest Wi-Fi 6 technology for fast, secure internet connection and an included DVD drive (a privilege on most modern laptops) so that you can access to old media or software installation from disks. A DVD drive is especially convenient for students and professionals who continue to utilize physical media. The laptop can also use external screens, making it a great choice for productivity-based setups in the home or office. It comes pre-loaded with Windows 11 Pro, offering advanced security functionalities and an easy-to-use interface designed for productivity. The one-time Microsoft Office lifetime license is also a big bonus, giving you unlimited access to handy programs like Word, Excel, and PowerPoint with no additional subscription fee. The addition of Copilot AI also enhances productivity, providing intelligent assistance in writing, editing, and data analysis. This limited time deal is awesome, make sure you don't miss it. See at Amazon
Yahoo
an hour ago
- Yahoo
Newspaper seeks public release of Centennial Park feasibility study
Niagara Falls City Council Chairman Jim Perry has talked with Mayor Robert Restaino about the unreleased feasibility study for the proposed Centennial Park arena and events campus and said he's encouraged by what he's been told about it so far. In response to questions from the Niagara Gazette on Thursday, Perry did not say whether he would support releasing the study to the public in response to a Freedom of Information Law request filed by the newspaper. Instead, Perry said he spoke to city attorney Tom DeBoy who acknowledged receipt of the newspaper's formal request for the document and was assured that the city's legal department is working on it. 'I'm not part of that process, but (DeBoy) assured me it's being done,' Perry said on Thursday. Restaino confirmed in an interview with the members of the local press on May 13 that he received what he described as an incomplete version of the study, which was prepared by the private Florida-based consulting firm Sports Facilities Advisory, LLC at a cost of $140,000, plus expenses. While he has since indicated that the study results support the city building Centennial Park, he has declined to release the contents publicly. In an interview with the Gazette earlier this week, Restaino said he intends to do so by the end of the month after the results are shared with 'stakeholders,' namely representatives from New York's lead economy development agency Empire State Development Corp. and National Grid, the two entities that covered the city's cost for the study. 'One of the things we will do is meet with the stakeholders who paid for the study and show it to them,' Restaino told the Gazette in an interview earlier this week. 'And then we'll release it to the public. This month everything is going to be out in the open.' During an appearance on Monday on 'Your Community Accountability with Sam and Jon,' a Falls-based social media program aired on Facebook and YouTube, Perry said he has had a 'lot of discussions about it' and that it 'looks positive.' On Thursday, Perry told the newspaper he hadn't seen the study but had talked to the mayor about it. 'I can't share everything because this will be up to the mayor to unveil, but this project should be one of the more positive advancements to our local economy I've seen in my 70-plus years here in the city if everything falls into place,' Perry said. On Thursday, the newspaper filed a formal Freedom of Information request with the city's legal department and clerk's office, requesting a copy of the study from Restaino's administration. The newspaper's request cited two opinions from the New York State Committee on Open Government that indicate state law allows public agencies to release documents in their possession even in instances where they are considered to be drafts or incomplete. 'Draft records are subject to FOIL,' said Paul Wolf, a Williamsville attorney and founder of the government transparency group, the New York Coalition for Open Government. The city clerk's office acknowledged the newspaper's request on Thursday afternoon. Under state law, public agencies are allowed up to 20 business days to either grant or deny requests for information. In its initial response, the city clerk's office indicated that should 'circumstances arise' that prevent the delivery of a response within 20 business, the newspaper would be contacted with a 'new response date.' 'Examples of circumstances that may lead to extended response times include staff shortages, requests for a large volume of records and requests that require significant document redaction and/or seek documents that are not maintained electronically,' the response from the clerk's office notes. The results of the feasibility study are expected to more clearly define elements of the Centennial Park project and shed light on whether it would, as proposed, be viable in the Falls. A previous arena study, commissioned by Niagara County in 2017, concluded that the city lacked a sufficient number of hotel rooms needed to support such a project at that time. City officials, including Restaino and Perry, are seeking to acquire, using the city's power of eminent domain, 10 acres of land currently owned by the private firm Niagara Falls Redevelopment for the purposes of building Centennial Park. The courts have sided with the city's argument that it has the right to forcibly acquire the property — located off John B. Daly Boulevard at the intersection of 10th and Falls streets — for the purposes of developing the 'park.' The city is currently engaged in litigation, arguing that 5 of those 10 acres are actually still owned by the city as NFR failed, more than a decade ago, to properly obtain permission from the state to annex what was at the time public parkland formerly known as 10th Street park. NFR is disputing the city's position in court. The company also insists it intends to use the 10 acres for the first phase of a project of its own, a proposed $1.5 billion data center it says it intends to build in partnership with the Canadian firm, Urbacon. During his interview on Sam Archie's social media program on Monday, Perry backed the city's position that the city, not NFR, owns the 5 acres because it was formerly public parkland that was never properly acquired by the company. He said he agrees with the city's position based on maps and other documents that show the area in question was a public park dating back to the 1940s. 'A park is a park forever until you get that it is no longer parkland by permission from the state,' he said. 'When it was transferred over, those papers were never filed,' he added. 'You can argue all you want, that is still a park. Unless it's done legally, there is no claim to it.' As to NFR — a company owned by the Milstein family of real estate developers in New York City — Perry said the city has heard 30 years of promises and stories from the company with no tangible results. He also said there 'is no two solutions,' a reference to what some residents and officials have suggested could be a compromise that would allow both projects to happen. 'The convention center is real,' Perry said, referring to Centennial Park, 'and I know that because I've been working on issues and I've been talking to people. The data center, to me, is another pie in the sky.' 'If we gave this fight up tomorrow, (and said), 'OK, you guys can have the park, we'll do the paperwork and turn it over to you.' Let them have it, turn it over to NFR, all the stuff, you know what's going to happen? They are going to say, 'Well, you took so long Urbacon's not interested in it anymore' because that's the M.O.' Perry did concede in his interview with show host Sam Archie that, if the city is successful in its claim for the 5 acres, it may be required to reimburse NFR for taxes paid on the property in the past. 'I would assume that is correct,' Perry said.
Yahoo
an hour ago
- Yahoo
Patents and economies of scale support Pfizer's wide moat
Pfizer's innovative business should grow faster after it divests its off-patent division Upjohn in 2020 to create Viatris and Mylan. With fewer older medications and fewer patent losses, Pfizer is well-positioned for consistent growth, excluding the erratic sales of Covid-19-related products. The company is less vulnerable to any one patent loss thanks to its wide range of medications. Because of its more complex manufacturing process and more affordable prices, Pfizer's stronger position in the vaccine marketwhich includes the pneumococcal vaccine Prevnarmakes it more resilient to generic competition. Warning! GuruFocus has detected 6 Warning Signs with PFE. With a 30% to 80% reduction, Trump's executive order would establish a "most favored nation" policy in which the US would pay the same amount for prescription medications as the nation with the lowest price. It is anticipated that this policy, which was previously blocked by courts, will reduce the US's annual drug spending of over $400 billion, saving taxpayers over a seven-year period. Given that drug prices in the United States are high when compared to other countries, Pfizer's U.S. revenue could be drastically impacted by the 30% to 80% price cut, especially for high-margin medications. International reference pricing policies have long been opposed by the pharmaceutical industry, which claims they could hinder innovation and limit access to new companies anticipate that the order will target Medicare and may have an impact on medications not covered by Biden's Inflation Reduction Act. President Trump has said that significant tariffs on pharmaceutical products will probably be announced soon. He has also put a 90-day hold on broader tariffs for the majority of his trading partners to give them time to negotiate. Despite being mostly exempt from tariffs, the biopharma industry is preparing for a possible pharma-specific announcement that might affect global manufacturing strategies. Products made in Europe and imported into the US may be subject to the rumored 25% tariff, necessitating the construction of new facilities that will take years to complete. Due to home country manufacturing, tax benefits, lower production costs, and exposure to currency fluctuations, businesses based in the US and Europe are heavily exposed to European manufacturing. Because drug spending is not cyclical, the direct effect of tariffs on earnings is probably going to be minimal, and the indirect effect of a possible recession should also be minimal. With the exception of small-scale US capacity expansions, biopharma is unlikely to completely reevaluate its manufacturing footprint if pharmaceutical tariffs are implemented but are lifted after 2026 as a result of political pressure from the midterm elections. Leadership in Vaccines Pfizer stands out with its dominant position in vaccines, most notably its highly successful COVID-19 vaccine developed in partnership with BioNTech. This vaccine not only generated significant revenue but also established Pfizer as a leader in mRNA technology, a platform with potential applications in oncology, rare diseases, and beyond. Johnson & Johnson (J&J): J&J also developed a COVID-19 vaccine, but it was less widely adopted due to lower efficacy rates and safety concerns, giving Pfizer a clear advantage in this high-impact area. GlaxoSmithKline (GSK): GSK has a strong vaccine portfolio (e.g., shingles and meningitis vaccines) but did not independently develop a COVID-19 vaccine, relying on partnerships like Sanofi, which delayed its entry and diminished its competitive stance. Bristol Myers Squibb (BMS): BMS has no significant presence in vaccines, focusing instead on oncology and immunology, making Pfizer's vaccine leadership a unique strength. R&D Capabilities and Pipeline Focus Pfizer's R&D efforts are concentrated on high-growth therapeutic areas such as oncology, vaccines, and rare diseases. Its ability to leverage mRNA technology and rapidly develop innovative therapies underscores its R&D prowess. J&J: J&J's R&D spans pharmaceuticals, medical devices, and consumer health. While this diversification provides stability, it may dilute J&J's focus on cutting-edge pharmaceutical innovation compared to Pfizer's targeted approach. GSK: GSK excels in respiratory diseases and HIV research, but its pipeline is less broad and lacks the same level of innovation in emerging technologies like mRNA that Pfizer is advancing. BMS: BMS has a strong oncology pipeline, particularly in immuno-oncology, but its narrower focus limits its competitiveness in other high-growth areas where Pfizer thrives, such as vaccines and rare diseases. Global Reach and Market Presence Pfizer operates in over 150 countries, giving it a vast global footprint that enhances its ability to distribute products and capture market share across both developed and emerging markets. J&J: J&J also has a global presence, but its focus is split across pharmaceuticals, medical devices, and consumer health, potentially reducing its pharmaceutical market penetration compared to Pfizer. GSK: GSK is strong in Europe and emerging markets but less dominant in the U.S., the world's largest pharmaceutical market, where Pfizer has a significant advantage. BMS: BMS focuses heavily on the U.S. and Europe, with less presence in emerging markets, limiting its global scale compared to Pfizer. Brand Reputation and Trust The success of Pfizer's COVID-19 vaccine has significantly boosted its brand recognition and trust among consumers, healthcare providers, and governments, reinforcing its market position. J&J: J&J enjoys a strong reputation in consumer health, but its pharmaceutical division lacks the same level of visibility and trust as Pfizer's, particularly after COVID-19 vaccine challenges. GSK: GSK is well-regarded in respiratory and HIV treatments but does not have the broad public recognition that Pfizer has achieved. BMS: BMS is respected in oncology but lacks the widespread brand prominence that Pfizer has cultivated. Innovation in Emerging Technologies Pfizer's investment in mRNA technology positions it as a pioneer in pharmaceutical innovation, with potential applications in vaccines, cancer treatments, and more, giving it a forward-looking edge. J&J: J&J innovates in medical devices and consumer health but trails Pfizer in adopting next-generation pharmaceutical technologies like mRNA. GSK: GSK focuses on innovation in respiratory and HIV treatments but has not made significant advances in mRNA or other emerging platforms. BMS: BMS drives innovation in immuno-oncology but lacks Pfizer's breadth and leadership in cutting-edge technologies. Pfizer's competitive edge over Johnson & Johnson, GlaxoSmithKline, and Bristol Myers Squibb lies in its unmatched leadership in vaccines, particularly through mRNA technology, combined with a robust R&D pipeline, extensive global reach, substantial financial resources, strong brand reputation, and a focus on innovation. While J&J benefits from diversification, GSK from efficiency, and BMS from oncology expertise, none rival Pfizer's comprehensive strengths across these critical areas, ensuring its dominance in the pharmaceutical landscape. Pfizer's broad moat is supported by patents, economies of scale, and a strong distribution network. Strong pricing power derived from Pfizer's patent-protected medications allows the company to produce returns on investment that exceed its cost of capital. The company can develop the next generation of drugs before generic competition appears thanks to the patents. Furthermore, even though Pfizer has a wide range of products, there is some product concentration, as Prevnar accounts for slightly more than 10% of total sales (not including sales of the COVID-19 vaccine).However, because of the vaccine's complicated manufacturing process and comparatively low cost, we don't anticipate typical generic competition. Ibrance and Eliquis each account for nearly 10% of sales. On the other hand, we anticipate that new products will eventually lessen the competition from generic versions of important medications. In order to lessen the pressure on margins from lost sales of high-margin drugs, Pfizer's operating structure permits cost-cutting after patent losses. All things considered, Pfizer's well-established product line generates the massive cash flows required to cover the typical $800 million in development expenses for each new medication. For smaller pharmaceutical companies without Pfizer's resources, the company's robust distribution network positions it as a solid partner. On April 15, President Donald Trump issued an executive order outlining possible policy changes intended to reduce the cost of pharmaceuticals in the United States. The biopharma industry is looking forward to these changes because they have the potential to either help or hurt innovation. In the worst situation, international price benchmarks have the potential to drastically cut US drug prices and lessen financial incentives for international drug development. On the plus side, eliminating the "pill penalty" that only grants small molecule medications nine years of Medicare negotiation protection may promote innovation across all treatment modalities. Trump's executive order may have a positive or negative impact on the industry, but it has no effect on valuations or uncertainty ratings. The protection period is not specified in Trump's request that US Department of Health and Human Services Secretary Robert F. Kennedy Jr. collaborate with Congress to address the pill penalty, which is contingent upon Congressional action. Since innovation and a favorable mergers and acquisitions climate support long-term pricing power and offset possible short-term tariff pressure, rising tax rates, and approval delays, the biopharma industry seems undervalued. Due to liver damage in a clinical trial, Pfizer has announced the discontinuation of danuglipron, an oral small molecule GLP-1 agonist. In the anticipated $200 billion global GLP-1 market by 2031, the company sought to provide a potential second-to-market oral small molecule GLP-1 agonist, behind Lilly's orforglipron. Clinical trial failures and declining demand for Pfizer's COVID vaccine and antiviral medication have hurt the company's growth. Because of its diverse pipeline and portfolio, Pfizer is expected to have a wide-moat case, protecting it from the effects of individual program failures, especially those involving high-risk programs like danuglipron. Other medication candidates might benefit from Pfizer's objective of turning danuglipron into a once-daily business could use its $15 billion acquisition budget to fund the development of more sophisticated medication candidates. Efforts in Genetic Engineering: A solid growth driver for Pfizer is the strong pipeline of innovative treatment options, especially in oncology and immunology, which take the leap with cutting-edge scientific technology. To be more specific, Pfizer's resource allocation to immuno-oncology is evident, developing of checkpoint inhibitors (e.g., PD-1/PD-L1 inhibitors) and chimeric antigen receptor T-cell (CAR-T) therapies. For instance, this method of treatment mitigates the immune system's ability to detect and destroy the specified cancer cells by varying the immune system response or, in some cases, by using specially modified T-cells that can identify the particular antigens on tumors that are solely expressed in those particular tumors, which are in question. This is the area of advancement where Pfizer has outdone the rest as they are perfecting monoclonal antibody formatsdesigning them in a way that they will bind more tightly and specifically to targets using protein engineeringand they are also testing out bispecific antibodies that trigger switches at two targets, therefore enhancing healing by more than one method. The pipeline is further supported by vast R&D investment in gene therapy and precision medicine, which utilize adeno-associated virus (AAV) vector platforms for gene delivery and next-generation sequencing for actionable mutation identification respectively. These endeavors are aimed at enhancing the overall patient health and market potential of the drugs by changing the treatment convention from testing a wide spectrum to one that is genotype-driven. Clinical trials are usually designed in a way to be fast-tracked so that they can move quickly to the next stage of development. By focusing on such advanced technologies, Pfizer is embarking on capturing a large section of the market with high-growth therapeutic branches, thus gaining revenue through innovation guided by complex disease biology. Revenue Growth: The launching of these high-value treatments is expected to increase revenue as well as drive down costs for Pfizer. Most of the drugs that are released in the onco-immunology field possess a technical edge and therapeutic effectiveness, therefore, these new treatements often demand high price. These drugs are capable of pumping up profits significantly once they clear regulatory hurdles and find their way onto the market. take the example of just-above successful immuno-oncology drug sales, which always have brisk selling and marvelous sales. In addition, Pfizer can speed-up the whole clinical process with something like adaptive trial designs, this process will be quicker and thus benefits are obtained faster from the new products. Impact on profitability The weight on profitability depends on the ratio of costs and returns. What is actually known is that lamas like the checkpoint inhibitors and CAR-T treatments that are so good require a lot of investment in R&D. But there is an inherent advantage for these drugs thanks to their patent protection that comes with market exclusivity, which in turn, allows Pfizer to keep its pricing strategy stick and generate very high profits. Success in the selling of the product along the lines of this new dimension along with the efficiency of producing more could prove to be the road to better profitability. However, there are barriers such as competition from other drug companies plus the worry of the price cuts from payers that can erode this success. So if Pfizer is able to eliminate the competition and stays ahead in the game by reducing costs as well, these high markups brought about by the introduction of such innovative drugs should positively affect the total profitability of the company. Generic competition, possible changes to government drug pricing policies, the more stringent FDA, and more powerful managed-care and pharmacy benefit managers present Pfizer with difficulties in drug development. In some disease areas, developing new drugs is getting harder, and pharmacy benefit managers and managed-care organizations have grown to be strong players with the ability to bargain for cheaper drug costs. Nearly one-fourth of the company's total sales are generated by its medications, Eliquis, Ibrance, and Xtandi, and they are heavily exposed to the Medicare channel. Given that Pfizer's product portfolio is less vulnerable to potential litigation, the company's base-case annual legal costs, assuming a 50% probability of future costs associated with product governance ESG risks, come close to 1% of non-GAAP net income. Pfizer's valuation multiples highlights their strong financial position and potential undervaluation. Their P/E Non-GAAP ratios7.61 (FY1), 7.42 (FY2), and 7.44 (FY3)are lower than JNJ's 14.00 (FY1) and SNY's 10.80 (FY1), suggesting investors may undervalue our earnings potential. The PEG Non-GAAP (FWD) of 1.49 is competitive, higher than SNY's 0.76 but below JNJ's 1.70, reflecting moderate growth prospects. Pfizer's EV/Sales (TTM) of 2.81 is more conservative than JNJ's 4.21, while the EV/EBITDA (FWD) of 7.13 compares favorably to JNJ's 11.45, indicating operational efficiency. The Price to Book (TTM) of 1.44 is significantly lower than JNJ's 5.23, and our Price to Cash Flow (TTM) of 9.29 beats JNJ's 15.67, underscoring robust cash flow generation. These metrics position Pfizer as a value opportunity among peers After the Seagen acquisition, Pfizer released its 2024 guidance, which included a $8 billion COVID-19 product guidance$5 billion less than anticipated. The business admitted that, excluding sales of COVID-19 products, it would not meet the prior growth-rate projection of 6% from 2020 to 2025. Pfizer reaffirmed its support for the dividend, which is regarded as safe and likely to boost stock valuation, despite the deteriorating outlook. Over the next ten years, the company anticipates steady sales as new products counteract older medications that are losing their patent protection. From the middle of 2023 to the end of 2024, Pfizer is anticipated to reduce operating expenses by $4 billion, which will aid the company in adjusting to the waning pandemic and declining sales of COVID-19 products. Growth could be accelerated through acquisitions, and future margin pressure could be reduced through restructuring initiatives. It is estimated that Pfizer's weighted average cost of capital is 7% and its cost of equity is 7.5%. Activist investor Jeffrey Smith's recent stake worth $407 million could presage the much needed turnarounds at Pfizer. Investors and shareholders can reasonably expect further cost-cuts and an efficient use of capital, leading to higher margins and free cashflow. This case could follow the path of Walt Disney, albeit with less drama, where Jeff Ubben of ValueAct had a pivotal role in Disney's turnaround campaign. The large-cap biopharma company Pfizer's debt size, business cyclicality, and debt maturity outlook all contribute to its sound balance sheet and low risk levels. To support opportunistic acquisitions and handle product litigation issues with little market concern, the company should have a strong enough balance sheet. Pfizer spends slightly less on R&D than the industry average, with a mid- to high-teens percentage of sales. Patent losses are offset by the company's robust pipeline of next-generation medications. The company's investment in cutting-edge new medications, mostly aimed at immunology and oncology, improves its standing and increases returns on capital. For biopharma companies in the sector, this balance sheet strength is essential. This article first appeared on GuruFocus. Sign in to access your portfolio
